Target ALS Foundation, focused on finding new treatments for amyotrophic lateral sclerosis (ALS), has selected RUCDR Infinite Biologics as the biorepository for banking and distributing the foundation’s human stem cell lines to be used in industry and research. The privately funded non-profit institution, funds consortia-based collaborative projects that aim to decrease obstacles…
News
Researchers at the University of Occupational and Environmental Health in Japan, reviewed advances for using natural plant compounds to regulate autophagy, a process in the development of many neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, muscular atrophies, spinocerebellar ataxia 3, and amyotrophic lateral sclerosis (ALS). The review “Natural compounds preventing…
Researchers reviewed both current and emerging technical approaches that show the most promise in the detection of upper motor neuron (UMN) degeneration of ALS patients. By assessing and comparing the utility of cutting-edge imaging and electrophysiological approaches, researchers hope to identify biomarkers for UMN dysfunction that can serve as early diagnostics for…
“Die Trying”, this Friday’s episode of HBO’s edgy half-hour newsmagazine series VICE, is about ALS and hosted by the show’s Senior Associate Editor Angelina Fanous who is battling the disease. A preview trailer can be viewed at: https://als.vice.com/. Living with ALS, Egyptian-born Fanous is now focusing on…
Researchers at the Karolinska Institute in Sweden and the University of Barcelona in Spain studied the contribution of cellular redox environment changes to the stability and integrity of SOD1, a protein implicated in the development and progression of familial amyotrophic lateral sclerosis (ALS). A key finding was that mutations in the…
Researchers at the University of California-Riverside have shown, for the first time, that infection from the common parasite Toxoplasma gondii disrupts neurotransmitter glutamate function in the brain, potentially leading to neuronal death and neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), in individuals predisposed to such conditions. The research paper, “…
Researchers from the Institute of Drug Research at the The Hebrew University in Israel have revealed that patients with amyotrophic lateral sclerosis (ALS) have low levels of the anti-inflammatory protein alpha-1-antitrypsin (AAT) in their cerebrospinal fluid (CSF). The findings have been published in the Journal of Neuroinflammation in the study…
Rapporteurs appointed by the European Medicines Agency (EMA) have recommended that AB Science SA’s combined treatment ‘masitinib with riluzole’ in the treatment of adults with amyotrophic lateral sclerosis (ALS) should be filed for conditional marketing authorization. AB Science specializes in developing and marketing protein kinase inhibitors (PKIs), a class of targeted proteins…
A multi-disciplinary team of researchers analyzed the genotype data of thousands of ALS patients, with the objective of identifying gene variants that influence survival in ALS. The genome-wide association study identified two novel loci that significantly influence patient survival. These key findings help researchers better understand the biology of the disease…
Amyotrophic lateral sclerosis (ALS) severely burdens skeletal muscles, while eye muscles remain far less affected. Vahid M. Harandi, a doctoral student at Umea University in Sweden, and his colleagues are focusing on the specific proteins involved in both areas’ response to ALS in an effort to better understand the pathophysiology…
Recent Posts
- ‘Early birds’ have significantly lower ALS risk than ‘night owls’: Study
- As my late husband’s ALS progressed, we kept our bucket list simple
- Tossing and turning over fears this ALS journey has come to its end
- Experimental ALS therapy QRL-201 shows potential to slow disease decline
- Worried about an inability to multitask? Here’s what helped me.